Key points are not available for this paper at this time.
Peptides that are composed of dextrorotary (d)-amino acids have gained increasing attention as a potential therapeutic class. However, our understanding of the in vivo fate of d-peptides is limited. This highlights the need for whole-body, quantitative tracking of d-peptides to better understand how they interact with the living body. Here, we used mouse models to track the movement of a programmed death-ligand 1 (PD-L1)-targeting d-dodecapeptide antagonist (DPA) using positron emission tomography (PET). More specifically, we profiled the metabolic routes of 64CuDPA and investigated the tumor engagement of 64Cu/68GaDPA in mouse models. Our results revealed that intact 64Cu/68GaDPA was primarily eliminated by the kidneys and had a notable accumulation in tumors. Moreover, a single dose of 64CuDPA effectively delayed tumor growth and improved the survival of mice. Collectively, these results not only deepen our knowledge of the in vivo fate of d-peptides, but also underscore the utility of d-peptides as radiopharmaceuticals.
Hu et al. (Wed,) studied this question.